Danna Jennings

9.7k citations

81 papers · 3.2k indexed · h-index 33

Neurology top 0.5%
- Parkinson's Disease Mechanisms and Treatments 42
- Neurological disorders and treatments 37
- Botulinum Toxin and Related Neurological Disorders 9
Cellular and Molecular Neuroscience top 2%
- Genetic Neurodegenerative Diseases 8
- Nuclear Receptors and Signaling 7
Psychiatry and Mental health top 2%
Sensory Systems top 2%
Neurology top 5%
- Parkinson's Disease Mechanisms and Treatments 42
- Neurological disorders and treatments 37
- Botulinum Toxin and Related Neurological Disorders 9
Cognitive Neuroscience
- Autism Spectrum Disorder Research 9
Physiology
- Alzheimer's disease research and treatments 7
Genetics
- Genetics and Neurodevelopmental Disorders 7

Co-authors: Kenneth Marek John Seibyl Shirley Eberly Andrew Siderowf David Oakes Gilles Tamagnan Mark A. Mintun Abhinay D. Joshi
Cited by: Neurology Cellular and Molecular Neuroscience Psychiatry and Mental health
Journals: NeuroImage (1 paper)Brain (2 papers)Neurology (11 papers)
Partner nations: United States Canada Switzerland

In The Last Decade

Danna Jennings

79 papers receiving 3.1k citations

Peers

Countries citing papers authored by Danna Jennings

Since Specialization

Citations

This map shows the geographic impact of Danna Jennings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danna Jennings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danna Jennings more than expected).

Fields of papers citing papers by Danna Jennings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danna Jennings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danna Jennings. The network helps show where Danna Jennings may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Danna Jennings, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Danna Jennings Line = papers co-authored together Danna Jennings links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Clinical Characterization of [¹⁸F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy Journal of Nuclear Medicine ·Cristian Constantinescu,Terry Brown,Shining Wang,Wei Yin,Olivier Barret,Danna Jennings,Johannes Tauscher	2023	2
2	Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome Brain Sciences ·James Robert Brašić,Ayon Nandi,David Russell,Danna Jennings,Olivier Barret,Anil Mathur,Keith J. Slifer,Thomas W. Sedlak,Samuel Martin,Zabecca Brinson,Pankhuri Vyas,John Seibyl,Elizabeth Berry‐Kravis,Dean F. Wong,Dejan B. Budimirovic	2020	12
3	Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) Journal of Parkinson s Disease ·Lana M. Chahine,Thomas G. Beach,Nicholas Seedorff,Chelsea Caspell‐Garcia,Christopher S. Coffey,Michael C. Brumm,Charles H. Adler,Geidy E. Serrano,Carly Linder,Sherri Mosovsky,Tatiana Foroud,Holly Riss,Dixie Ecklund,John Seibyl,Danna Jennings,Vanessa Arnedo,Lindsey Riley,Kuldip D. Dave,Brit Mollenhauer,(unknown)	2018	15
4	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition Brain ·Michael J. Pontecorvo,Michael D. Devous,Michael Navitsky,Ming‐Chi Lu,Stephen Salloway,Frederick W. Schaerf,Danna Jennings,Anupa Arora,Anne McGeehan,Nathaniel C. Lim,Hui Xiong,Abhinay D. Joshi,Andrew Siderowf,Mark A. Mintun,(unknown)	2017	263
5	Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease Parkinson s Disease ·William Seiple,Danna Jennings,Richard B. Rosen,Leona D. Borchert,Lee Canale,Nora Fagan,Mark Forrest Gordon	2016	4
6	Assessment of Parkinson disease progression using 123- I I-Ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial (I11-5C) Neurology ·John Seibyl,Danna Jennings,Kenneth Marek	2015	1
7	In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: ¹⁸F-MNI-659 and ¹⁸F-MNI-654 Journal of Nuclear Medicine ·Olivier Barret,David Thomae,Adriana Tavares,David Alagille,Caroline Papin,Rikki N. Waterhouse,Timothy J. McCarthy,Danna Jennings,Kenneth Marek,David Russell,John Seibyl,Gilles Tamagnan	2014	51
8	Brain distribution of BZM055, an analog of fingolimod (FTY720), in human Multiple Sclerosis Journal ·Gilles Tamagnan,Adriana Tavares,Olivier Barret,D Alagille,John Seibyl,Kenneth Marek,R. P. Maguire,Emmanuelle Briard,Robert Schmouder,Rhett Behrje,Danna Jennings	2012	10
9	Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study Movement Disorders ·Andrew Siderowf,Danna Jennings,Shirley Eberly,David Oakes,Keith A. Hawkins,Albert Ascherio,Matthew B. Stern,Kenneth Marek,(unknown)	2012	144
10	Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects Journal of Nuclear Medicine ·Abhinay D. Joshi,Michael J. Pontecorvo,Chrisopher M. Clark,Alan Carpenter,Danna Jennings,Carl Sadowsky,Lee P. Adler,Karel D. Kovnat,John Seibyl,Anupa Arora,Krishnendu Saha,Jason Burns,Mark Lowrey,Mark A. Mintun,Daniel Skovronsky,(unknown)	2012	301
11	First in vivo assessment of two PDE10 tracers [18F]MNI654 and [18F]MNI659 Olivier Barret,David Thomae,David Alagille,Hsiaoju Lee,Caroline Papin,Ronald M. Baldwin,Danna Jennings,Kenneth Marek,John Seibyl,Gilles Tamagnan	2012	9
12	Neuroimaging Over the Course of Parkinson's Disease: From Early Detection of the At-Risk Patient to Improving Pharmacotherapy of Later-Stage Disease Seminars in Nuclear Medicine ·John Seibyl,David Russell,Danna Jennings,Kenneth Marek	2012	17
13	Molecular PET imaging in multicenter Alzheimer’s therapeutic trials: current trends and implementation strategies Expert Review of Neurotherapeutics ·John Seibyl,I. George Zubal,Danna Jennings,Kenneth Marek,P. Murali Doraiswamy	2011	4
14	Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: A β-CIT imaging study Neurobiology of Disease ·Richard F. Seegal,Kenneth Marek,John Seibyl,Danna Jennings,Eric Molho,Donald S. Higgins,Stewart A. Factor,Edward F. Fitzgerald,Elaine A. Hills,Susan Korrick,Mary S. Wolff,Richard F. Haase,Andrew C. Todd,Patrick J. Parsons,Robert J. McCaffrey	2010	41
15	FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients Parkinsonism & Related Disorders ·Deborah J. Hall,Danna Jennings,John Seibyl,F. Tassone,Kenneth Marek	2010	19
16	Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression Annals of Neurology ·Kenneth Marek,Danna Jennings,Gilles Tamagnan,John Seibyl	2009	48
17	Phenotypic spectrum and sex effects in eleven myoclonus‐dystonia families with ε‐sarcoglycan mutations Movement Disorders ·Deborah Raymond,Rachel Saunders‐Pullman,Patrícia de Carvalho Aguiar,Birgitt Schüle,Norman Kock,Jennifer Friedman,Juliette Harris,Blair Ford,Steven J. Frucht,Gary A. Heiman,Danna Jennings,Dana Doheny,Mitchell F. Brin,Deborah de Leon Brin,Trisha Multhaupt‐Buell,Anthony E. Lang,Roger Kurlan,Christine Klein,Laurie J. Ozelius,Susan Bressman	2008	35
18	Interest in predictive testing for Parkinson's disease: Impact of neuroprotective therapy Parkinsonism & Related Disorders ·Nabila Dahodwala,James L. Connolly,Jennifer Farmer,M. B. Stern,Danna Jennings,Andrew Siderowf	2007	15
19	[¹²³I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy Movement Disorders ·Andrea Varrone,Kenneth Marek,Danna Jennings,Robert B. Innis,John Seibyl	2001	126
20	Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31 Annals of Neurology ·Torbjoern G. Nygaard,Deborah Raymond,Caiping Chen,Ichizo Nishino,Paul Greene,Danna Jennings,Gary A. Heiman,Christine Klein,Rachel J. Saunders-Pullman,Patricia Kramer,Laurie J. Ozelius,Susan Bressman	1999	71

About Danna Jennings

Danna Jennings is a scholar working on Neurology, Cellular and Molecular Neuroscience and Cognitive Neuroscience, having authored 81 papers that have together received 3.2k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (42 papers), Neurological disorders and treatments (37 papers), Botulinum Toxin and Related Neurological Disorders (9 papers), Autism Spectrum Disorder Research (9 papers), Genetic Neurodegenerative Diseases (8 papers), Alzheimer's disease research and treatments (7 papers), Genetics and Neurodevelopmental Disorders (7 papers) and Nuclear Receptors and Signaling (7 papers). The work is most often cited by research in Neurology (1.8k citations), Cellular and Molecular Neuroscience (720 citations) and Psychiatry and Mental health (584 citations). Danna Jennings has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Kenneth Marek, John Seibyl, Shirley Eberly, Andrew Siderowf, David Oakes, Gilles Tamagnan, Mark A. Mintun, Abhinay D. Joshi, Anupa Arora and Michael J. Pontecorvo. Their work appears in journals such as NeuroImage, Brain and Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact